Clinical collaboration Strategic partnership opportunities with contract research organizations and cancer research centers given Dialectic’s clinical stage status, active collaborations with UT Health San Antonio and University of Florida Health, and recent drug supply partnership for a fibrolamellar cancer trial.

Fibrofoundation tie Leverage the April 2025 Fibrolamellar Cancer Foundation partnership to position DT2216 for expanded trials in rare liver cancer indications and pediatric-adult fibrolamellar patient recruitment and funding opportunities.

Financial runway Mid-stage funding profile with modest revenue and a $20M funding stack suggests readiness for co-development deals, milestone-based partnerships, and potential licensing discussions with larger biopharma players seeking early-stage oncology assets.

Targeted therapy Focus on delivering targeted therapies with limited toxicities aligns with partner interest from academic and hospital systems; explore opportunities in companion diagnostics, biomarkers, and precision oncology collaborations to de-risk trial enrollment.

Strategic exposure Small team size and Texas-based operations present a lean development model; propose channeling sales through CROs, academic consortia, and regional biopharma alliances to scale studies efficiently while expanding geographic and indication reach.